Conflicting reports of stromal versus tumour PD-L1 staining, coupled with the lack of standardization, proprietary nature and the difficulties associated with PD-L1 as an IHC antigen have precluded the routine use of this marker in the clinic. This evidence concerns the gene CD274 and neoplasm.